RxDoctor Payments Data

Javid Amini, MD

Cardiovascular Disease · Kingston, PANPI 1689609638

Payments from drug & device makers

$13,822in general payments, 2019–2025

Across 565 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Novartis$1K
  • Amgen$989
  • Pfizer$890
  • AstraZeneca$795
  • plus $3K from 20 others

What the payments were for

  • Travel & lodging$3,61326%
  • Food & beverage$10,19574%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,822 in reported general payments places this provider in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$449,845
Medicare patients
1,686
Services billed
6,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban534$507,719
BrilintaTicagrelor118$86,924
XareltoRivaroxaban81$84,929
EntrestoSacubitril/Valsartan34$33,084
Isosorbide Mononitrate ErIsosorbide Mononitrate496$7,447
Metoprolol Succinate411$6,346
ClopidogrelClopidogrel Bisulfate338$5,867
Losartan Potassium463$4,838
Atorvastatin Calcium421$4,417
Ranolazine ErRanolazine41$4,350
Amiodarone Hcl73$3,475
Isosorbide Dinitrate60$3,074
Icosapent Ethyl11$3,069
Metoprolol Tartrate520$2,628
Labetalol Hcl76$2,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$890$507,719534 claims
AstraZenecaBrilinta$795$86,924118 claims
Johnson & JohnsonXarelto$636$84,92981 claims
NovartisEntresto$1,345$33,08434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →